Develops and manufactures tools for genomic and proteomic analysis. Offers the nCounter Analysis System for automated digital detection and counting of molecules. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
No real growth (4% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $127.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 56 buys and 38 sells. Management buying with its own money is usually read as a good sign.
A loss of $159.5M against $127.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.11. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.